Tempus AI, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TEM in the last 30 days.
See all $TEM insider activity →Tempus AI (TEM) is set to report Q3 earnings around Nov. 2, with revenue expected to grow 22.5% YoY to $409.37M. The company has a pending $1.5B acquisition of Personalis (PSNL) and raised FY2026 revenue guidance to $1.595B-$1.605B. Shares are down 20.36% over the past month.
Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.
H.C. Wainwright raised its price target on Tempus AI (TEM) to $68 from $66, maintaining a Buy rating. The stock trades at $67.61 with a $12.2B market cap. Tempus announced expanded agreements with Bristol Myers Squibb and Pathos AI, potentially bringing in up to $192.5M over five years. Analysts have mixed ratings and targets on TEM.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning TEM (Tempus AI, Inc.). Coverage has skewed bullish: 9 bullish, 1 neutral, and 1 bearish.
Recent TEM coverage spans financial news, earnings and technology.
The stock may face near‑term pressure as investors await the earnings release and assess the Personalis deal.
The cash gap and debt load create downside pressure on the stock.
Analyst upgrade and higher target may lift sentiment.
The deal provides Tempus with a high‑profile customer, likely boosting revenue outlook.
Pathos AI partnered with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's and other neurological disorders. The company raised $237 million in a Series E funding round led by Bristol Myers, valuing it at $3 billion. Pathos will license data from Tempus for $55 million over five years and use its AI platform, Pathos Foundry, to study the dataset and design clinical trials. Bristol Myers gains non-exclusive access to Pathos Foundry.
AlphAI scores every news story that mentions TEM with an AI model for sentiment and relevance, and aggregates insider trades from Tempus AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tempus AI (TEM) is set to report Q3 earnings around Nov. 2, with revenue expected to grow 22.5% YoY to $409.37M. The company has a pending $1.5B acquisition of Personalis (PSNL) and raised FY2026 revenue guidance to $1.595B-$1.605B. Shares are down 20.36% over the past month.
2 min readTempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.
2 min readH.C. Wainwright raised its price target on Tempus AI (TEM) to $68 from $66, maintaining a Buy rating. The stock trades at $67.61 with a $12.2B market cap. Tempus announced expanded agreements with Bristol Myers Squibb and Pathos AI, potentially bringing in up to $192.5M over five years. Analysts have mixed ratings and targets on TEM.
2 min readTempus AI (TEM) and Bristol Myers Squibb (BMY) extended their collaboration with a multi-year agreement. BMY will license Tempus' oncology data through 2031 and access its AI-driven Lens Platform for drug discovery. The deal expands their existing partnership in AI and data-driven oncology research.
2 min readPathos AI partnered with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's and other neurological disorders. The company raised $237 million in a Series E funding round led by Bristol Myers, valuing it at $3 billion. Pathos will license data from Tempus for $55 million over five years and use its AI platform, Pathos Foundry, to study the dataset and design clinical trials. Bristol Myers gains non-exclusive access to Pathos Foundry.
2 min readTempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data
2 min readTempus AI (TEM) stock fell 17.3% in the past month, despite 22% quarterly sales growth. Its deal with AstraZeneca runs until at least 2026, possibly 2028, with potential revenue risks from pricing discounts. Data and Apps unit, 25% of sales, grew 28%. Tempus reported a $254M net loss, trading at 8.1x sales, down from 11.6x a year ago.
2 min readTempus AI reported >80% sensitivity in its AI NSCLC pre-screening panel across 12 biomarkers, with some >90%, from a 60,459-case analysis presented at ESMO 2026. The tool is in development to prioritize confirmatory testing.
2 min readTempus AI's developing tool identified over 80% of cases with 12 treatment-linked signs in lung cancer images, analyzing 60,459 advanced NSCLC cases. The AI panel predicts genomic and IHC biomarkers from pathology images, aiming to prioritize diagnostic testing. Tempus collaborated with Pfizer on the study, which builds on their AI-enabled biomarker prediction work. The tool is not intended to replace established testing but to inform subsequent diagnostics.
2 min readTempus AI, Inc. (TEM) will release Q3 2026 earnings on Nov. 2, 2026, before market open, followed by a webcast at 8:45 a.m. ET. The company has not yet provided specific financial guidance or updates.
1 min read
